SWK Holdings Updates Portfolio Amid Active Financial Movements

SWK Holdings Corporation, a specialty finance firm, shared recent developments in its portfolio, highlighting several key financial activities since September 30, 2024. In November, the company advanced $5 million to Journey Medical to aid the launch of EmrosiTM and $0.6 million to Biotricity, securing 600,000 stock warrants at $0.50 per share. December saw an $8 million loan to Triple Ring Technologies, plus $2.5 million loans each to SKNV and MedMinder. Additionally, SWK expanded its credit facility with Eton by $25.7 million, receiving 289,736 stock warrants.

On the repayments front, SWK collected $3.4 million from Exeevo asset sales, with expectations for further payments. A $13 million payment was received from the Biolase bankruptcy estate. Payments of $1.9 million from Trio Healthcare and $4.2 million from Veru followed. January closed with a $12.2 million payment from Moleculight, clearing its debt obligations.